TG Therap released FY2025 Semi-Annual Earnings on August 4 Pre-Market (EST), actual revenue USD 262 M, actual EPS USD 0.1999

Brief Summary

TG Therapeutics reported a revenue of $262 million and an EPS of $0.1999 for the first half of fiscal year 2025.

Impact of The News

The financial briefing of TG Therapeutics indicates a positive momentum in their business, with a notable increase in revenue.

Financial Performance:

• The company reported total revenue of $262 million for the first half of 2025 with an EPS of $0.1999.

Comparison with Peers:

• Compared to some peers, such as BioCryst Pharmaceuticals which also demonstrated significant revenue growth, TG Therapeutics shows strong performance in revenue growth, especially with the increase in Briumvi’s net income which is a substantial contributor to their revenue Reuters+ 2.

Market Expectation and Business Status:

• TG Therapeutics’ revenue aligns well with its strategic goals, as the company has increased its revenue target for Briumvi in the U.S. to $570 million to $575 million for 2025 Reuters. The financial results suggest a positive trend, suggesting that the company is on track to meet its revenue targets.

Future Business Development Trends:

• The significant growth in Briumvi’s revenue, which increased from $72.6 million to $138.8 million, indicates a strong market acceptance of TG Therapeutics’ products. This trend is likely to continue, positioning the company for sustained growth in the coming quarters Reuters.